Read by QxMD icon Read

Gynecologic Oncology

Wilberto Nieves-Neira, J Julie Kim, Daniela Matei
No abstract text is available yet for this article.
June 20, 2018: Gynecologic Oncology
Marcela G Del Carmen
No abstract text is available yet for this article.
June 19, 2018: Gynecologic Oncology
Beryl L Manning-Geist, Katherine Hicks-Courant, Allison A Gockley, Rachel M Clark, Marcela G Del Carmen, Whitfield B Growdon, Neil S Horowitz, Ross S Berkowitz, Michael G Muto, Michael J Worley
OBJECTIVES: To examine the relationship between volume of residual disease and oncologic outcomes among patients with advanced-stage epithelial ovarian/fallopian tube/primary peritoneal carcinoma undergoing primary debulking surgery (PDS). For patients that did not undergo a complete surgical resection (CSR), a surrogate for volume of residual disease was used to assess oncologic outcomes. METHODS: Medical records of patients with FIGO stage IIIC and IV epithelial ovarian/fallopian tube/primary peritoneal carcinoma undergoing PDS between January 2010 and November 2014 were reviewed...
June 19, 2018: Gynecologic Oncology
Brian J Gebhardt, John A Vargo, Hayeon Kim, Christopher J Houser, Scott M Glaser, Paniti Sukumvanich, Alexander B Olawaiye, Joseph L Kelley, Robert P Edwards, John T Comerci, Madeleine Courtney-Brooks, Sushil Beriwal
PURPOSE: Brachytherapy is integral to vaginal cancer treatment and is typically delivered using an intracavitary single-channel vaginal cylinder (SCVC) or an interstitial brachytherapy (ISBT) applicator. Multi-channel vaginal cylinder (MCVC) applicators allow for improved organ-at-risk (OAR) sparing compared to SCVC while maintaining target coverage. We present clinical outcomes of patients treated with image-based high dose-rate (HDR) brachytherapy using a MCVC. METHODS AND MATERIALS: Sixty patients with vaginal cancer (27% primary vaginal and 73% recurrence from other primaries) were treated with combination external beam radiotherapy (EBRT) and image-based HDR brachytherapy utilizing a MCVC if residual disease thickness was 7 mm or less after EBRT...
June 18, 2018: Gynecologic Oncology
Malcolm S Ross, Mary E Burriss, Daniel G Winger, Robert P Edwards, Madeleine Courtney-Brooks, Michelle M Boisen
OBJECTIVES: Previous studies have identified age, nutritional status, and hematocrit as risk factors for unplanned ICU admission in gynecologic oncology patients. We sought to identify additional perioperative factors that can be predictive of unplanned ICU admission and its impact on outcomes in women with ovarian cancer undergoing ovarian cancer cytoreductive procedures. METHODS: This was a case-control study of patients with unplanned ICU admission after primary surgery for ovarian cancer from January 2007 to December 2013...
June 18, 2018: Gynecologic Oncology
Rachel M Clark, Laurel W Rice, Marcela G Del Carmen
OBJECTIVES: Thirty-day readmission rate has been proposed as metric of quality and remains an ongoing clinical concern in the primary treatment of patients with advanced-stage ovarian epithelial ovarian cancer. We conducted a review of the literature to identify rates, risk factors, and predictors for 30-day readmission in this population. METHODS: A 10-year period MEDLINE (PubMed) search of English literature studies published between January 01, 2008-January 01, 2018 was performed to identify appropriate studies for review...
June 18, 2018: Gynecologic Oncology
Renata R Urban, Todd C Pappas, Rowan G Bullock, Donald G Munroe, Vinicius Bonato, Kathy Agnew, Barbara A Goff
OBJECTIVE: To assess the performance of a symptom index (SI) and multivariate biomarker panel in the identification of ovarian cancer in women presenting for surgery with an adnexal mass. STUDY DESIGN: Prospective study of patients seen at a tertiary medical center. Following consent, patients completed an SI and preoperative serum was collected for individual markers (CA 125) and a second-generation FDA-cleared biomarker test (MIA2G). Results for the SI and MIA2G were correlated with operative findings and surgical pathology...
June 18, 2018: Gynecologic Oncology
Diogo Torres, Chen Wang, Amanika Kumar, Jamie N Bakkum-Gamez, Amy L Weaver, Michaela E McGree, Gottfried E Konecny, Ellen L Goode, William A Cliby
OBJECTIVE: To investigate the relationship between molecular subtype, intraperitoneal (IP) disease dissemination patterns, resectability, and overall survival (OS) in advanced high-grade serous ovarian cancer (HGSOC). METHODS: Patients undergoing primary surgery for stage III-IV HGSOC at Mayo Clinic from 1994 to 2011 were categorized into three IP disease dissemination patterns: upper abdominal or miliary; lower abdominal; and pelvic. Residual disease was defined as 0 (RD0), 0...
June 17, 2018: Gynecologic Oncology
John K Chan, William Brady, Bradley J Monk, Jubilee Brown, Mark S Shahin, Peter G Rose, Jae-Hoon Kim, Angeles Alvarez Secord, Joan L Walker, David M Gershenson
OBJECTIVES: To determine the efficacy and tolerability of sunitinib in recurrent or persistent clear cell ovarian cancer patients. METHODS: All patients had one or two prior regimens with measurable disease. Tumors were at least 50% clear cell histomorphology and negative for WT-1 antigen and estrogen receptor expression by immunohistochemistry. Sunitinib 50 mg per day for 4 weeks was administered in repeated 6-week cycles until disease progression or prohibitive toxicity...
June 16, 2018: Gynecologic Oncology
Na Li, Xiaohan Zhan, Xianquan Zhan
BACKGROUND: Malignant tumors are heterogeneous diseases characterized by different metabolic phenotypes. These were revealed by Warburg effect and reverse Warburg effect phenotypes. However, the molecular mechanism remains largely unknown. METHODS: Isobaric tag for relative and absolute quantification (iTRAQ) proteomics was used to identify mitochondrial differentially expressed proteins (DEPs) of ovarian cancers relative to controls, followed by bioinformatic analysis...
June 16, 2018: Gynecologic Oncology
Noémie Body, Jean Grégoire, Marie-Claude Renaud, Alexandra Sebastianelli, Katherine Grondin, Marie Plante
OBJECTIVE: To determine the validity of sentinel lymph node (SLN) biopsy with ICG in endometrial cancer and to evaluate the factors associated with poor mapping or false negative. METHODS: We reviewed all patients who underwent primary surgery for endometrial carcinoma with SLN mapping using ICG followed by pelvic lymphadenectomy from February 2014 to December 2015. SLNs were ultrastaged on final pathology. Patients' demographics, surgical approach and histopathological factors were prospectively collected...
June 14, 2018: Gynecologic Oncology
Ilana Graetz, Janeane N Anderson, Caitlin N McKillop, Edward J Stepanski, Andrew J Paladino, Todd D Tillmanns
OBJECTIVE: Nearly 1 in 5 patients hospitalized for ovarian cancer surgery are readmitted for complications that may have been prevented with monitoring. We conducted a randomized controlled feasibility trial to evaluate a postoperative web-based app intervention to provide real-time symptom monitoring among patients diagnosed or with suspected gynecological cancer who had open bilateral salpingo-oophorectomy surgery. METHODS: Participants were randomized into two groups: (1) App + Reminder: had access to the app, and use was encouraged with daily and/or weekly reminders; (2) app: had access to the app but received no reminders...
June 11, 2018: Gynecologic Oncology
Pierre-Adrien Bolze, Mélodie Mathe, Touria Hajri, Benoit You, Yohann Dabi, Anne-Marie Schott, Sophie Patrier, Jérôme Massardier, François Golfier
BACKGROUND: Low-risk gestational trophoblastic neoplasia (GTN) patients (FIGO score ≤6) are generally treated with single agent chemotherapy (methotrexate or dactinomycin) resulting in a 5-year mortality rate of 0.3%. However, despite these encouraging survival rates, chemotherapy is associated with significant adverse events in most patients. Although it is generally accepted that patients who no longer wish to conceive may be treated by hysterectomy for a hydatidiform mole, the evidence to support this strategy in low-risk GTN patients is lacking...
June 8, 2018: Gynecologic Oncology
J Michael Straughn, Teresa Boitano, Haller J Smith, Sarah E Dilley, Margaret I Liang, Lea Novak
A 32 year-old nulligravid woman with a uterine mass underwent exploratory laparotomy with myomectomy. Final pathology revealed a low-grade endometrial stromal sarcoma (ESS) with positive margins. She subsequently underwent definitive robotic hysterectomy and bilateral salpingectomy with ovarian preservation. She was diagnosed with a stage IB low-grade ESS. She is currently undergoing observation. Discussion of classification, surgical options, and adjuvant therapy is presented.
June 7, 2018: Gynecologic Oncology
Alessandro Buda, Maria Luisa Gasparri, Andrea Puppo, Liliana Mereu, Elena De Ponti, Giampaolo Di Martino, Antonia Novelli, Saverio Tateo, Michael Muller, Fabio Landoni, Andrea Papadia
OBJECTIVE: The aim of this study was to determine the impact of the sentinel lymph node mapping algorithm (SLN-A) on the staging in high-risk endometrial cancer (EC) compared to SLN plus selective lymphadenectomy (S-LND). METHODS: We retrospectively analyzed the database from a multicenter collaboration that included women with high risk features who underwent primary surgical staging. RESULTS: One-hundred and seventy-one women were identified (171), 66 in the SLN-A and 105 in the S-LND group, respectively...
June 7, 2018: Gynecologic Oncology
Rachana Shah, Caihong Xia, Mark Krailo, James F Amatruda, Suren G Arul, Deborah F Billmire, William E Brady, Allan Covens, David M Gershenson, Juliet P Hale, Jean Hurteau, Matthew J Murray, James C Nicholson, Thomas A Olson, Farzana Pashankar, Carlos Rodriguez-Galindo, Furqan Shaikh, Daniel Stark, A Lindsay Frazier, Sara Stoneham
OBJECTIVE: Dysgerminoma is the most common malignant ovarian germ cell tumor (GCT) with peak incidence during adolescence and young adulthood. Current standard of care for patients with disease that has spread outside of the ovary (advanced-stage) utilizes platin-based chemotherapy regimens. The study objective was to compare clinical outcomes between platin-based (carboplatin versus cisplatin) strategies across all age groups (children < 11 years (y), adolescents = 11-25 y and young adult women > 25 y) for advanced-stage dysgerminoma...
June 5, 2018: Gynecologic Oncology
J M Woolderink, G H De Bock, J A de Hullu, H Hollema, R P Zweemer, B F M Slangen, K N Gaarenstroom, M van Beurden, H C van Doorn, R H Sijmons, H F A Vasen, M J E Mourits
OBJECTIVE: To describe clinical characteristics of Lynch syndrome associated ovarian cancer and the efficacy of surveillance in the early detection of these ovarian cancers. METHODS: All Lynch syndrome associated ovarian cancer cases identified in either the Dutch Lynch syndrome registry (DLSR) between 1987 and 2016, and/or the cohort at the University Medical Center Groningen (UMCG) between 1993 and 2016 were included. Clinical data on age at diagnosis, mutation type, histological type, FIGO stage, treatment, follow-up and gynecological surveillance were collected...
June 4, 2018: Gynecologic Oncology
S Stolnicu, I Barsan, L Hoang, P Patel, C Terinte, A Pesci, S Aviel-Ronen, T Kiyokawa, I Alvarado-Cabrero, E Oliva, K J Park, N R Abu-Rustum, M C Pike, R A Soslow
OBJECTIVE: The Silva invasion pattern-based classification system stratifies endocervical adenocarcinomas (ECAs) into 3 categories corresponding to risk of metastasis and recurrence, but has only been evaluated for HPV-associated ECAs of usual type. We examined whether the Silva system is applicable to all endocervical adenocarcinomas, especially those not associated with HPV. METHODS: Complete slide sets from 341 surgical specimens of ECA were collected from 7 institutions worldwide...
May 30, 2018: Gynecologic Oncology
Rebecca C Arend, Bayley A Jones, Alba Martinez, Paul Goodfellow
Endometrial cancer is the most prevalent gynecologic cancer in the United States. Over the last 10 years, death rates from endometrial cancer have been rising about 1.4% per year. Traditionally endometrial cancer treatment has been driven by stage and histology. Recent studies have, however, shown that cancers of the same stage and histology have very distinct molecular and genomic profiles. Translational research is progressing rapidly and endometrial cancer-specific precision medicine is evolving. The first tissue agnostic therapy based on the molecular profile of the tumor was approved by the FDA this year...
May 27, 2018: Gynecologic Oncology
Kristina Lindemann, Bo Gao, Cristina Mapagu, Sian Fereday, Catherine Emmanuel, Kathryn Alsop, Nadia Traficante, Paul R Harnett, David D L Bowtell, Anna deFazio
OBJECTIVE: The aim of this study was to compare response rates and survival in women with "platinum resistant" epithelial ovarian cancer (EOC) who received further platinum-based or non‑platinum chemotherapy for treatment at first relapse. METHODS: Patients with high-grade EOC (including fallopian tube and peritoneal cancer) of all histologies recruited to the Australian Ovarian Cancer Study (AOCS) and treated with platinum-based primary chemotherapy were included...
May 25, 2018: Gynecologic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"